Oncotarget

Reviews:

Addressing intra-tumoral heterogeneity and therapy resistance

Brad Rybinski, Kyuson Yun _

PDF |  HTML  |  Order a Reprint

Oncotarget. 2016; 7:72322-72342. https://doi.org/10.18632/oncotarget.11875

Metrics: PDF 465 views  |   HTML 418 views  |   ?  


Abstract

Brad Rybinski1 and Kyuson Yun2,3

1 Albert Einstein College of Medicine, Bronx, NY, USA

2 The Jackson Laboratory, Bar Harbor, ME, USA

3 Present Address: Houston Methodist Research Institute, Department of Neurosurgery, Houston, TX, USA

Correspondence to:

Kyuson Yun, email:

Keywords: epigenetic, heterogeneity, therapy resistance, cancer stem cells, microenvironment

Received: April 18, 2016 Accepted: August 24, 2016 Published: September 06, 2016

Abstract

In the last several years, our appreciation of intra-tumoral heterogeneity has greatly increased due to accumulating evidence for the co-existence of genetically and epigenetically divergent cancer cells residing in different microenvironments within a tumor. Herein, we review recent literature discussing intra-tumoral heterogeneity in the context of therapy resistance mechanisms at the genetic, epigenetic and microenvironmental levels. We illustrate the influence of tumor microenvironment on therapy resistance and epigenetic states of cancer cells by highlighting the role of cancer stem cells in therapy resistance. We also summarize different strategies that have been employed to address various resistance mechanisms at genetic, epigenetic, and microenvironmental levels in preclinical and clinical studies. We propose that future personalized cancer therapy design needs to incorporate dynamic and comprehensive analyses of tumor heterogeneity landscape and multi-dimensional mechanisms of therapy resistance.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 11875